

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A01N 31/08, A61K 31/05, C07K 14/52, 14/47	A1	(11) International Publication Number: WO 97/09877 (43) International Publication Date: 20 March 1997 (20.03.97)
(21) International Application Number: PCT/US96/14725 (22) International Filing Date: 13 September 1996 (13.09.96) (30) Priority Data: 60/003,799 14 September 1995 (14.09.95) US (71) Applicant: RESEARCH DEVELOPMENT FOUNDATION [US/US]; 402 North Division Street, Carson City, NV 89703 (US). (72) Inventor: AGGARWAL, Bharat, B.; 3920 Oberlin, Houston, TX 77005 (US). (74) Agent: WEILER, James, F.; Suite 1560, 1 Riverway, Houston, TX 77056 (US).		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: CURCUMIN (DIFERULOYLMETHANE) INHIBITION OF NF κ B ACTIVATION (57) Abstract The present invention provides a method of inhibiting the activation of the NF- κ B transcription factor in an animal in need of such treatment comprising the step of administering to said animal a pharmacologically effective dose of curcumin. Also provided is a method of inhibiting the nuclear translocation of the p65 subunit of the NF- κ B transcription factor in a cell or in an animal in need of such treatment comprising the step of administering to said animal a pharmacologically effective dose of curcumin.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

- 1 -

**CURCUMIN (DIFERULOYLMETHANE) INHIBITION
OF NF- κ B ACTIVATION**

BACKGROUND OF THE INVENTION

Field of the Invention

5 The present invention relates generally to the fields of immunology and protein chemistry. More specifically, the present invention relates to the use of curcumin to inhibit activation of the transcription factor, NF- κ B.

Description of the Related Art

10 Members of the transcription factor NF- κ B family play a central role in various responses leading to host defense, activating a rapid progression of gene expression. These transcription factors are dimeric complexes composed of different members of the Rel/NF- κ B family of polypeptides. This family is
15 distinguished by the presence of a Rel homology domain of about 300 amino acids that displays a 35 percent to 61 percent identity between various family members (for references see 1). Although NF- κ B is a ubiquitous transcription factor, it plays a critical role in the cells of the immune system, where it controls the
20 expression of various cytokines and the major histocompatibility complex genes. The inappropriate regulation of NF- κ B and its dependent genes have been associated with various pathological conditions including toxic/septic shock, graft vs host reaction, radiation damage, atherosclerosis, and cancer (1, 2). Thus,
25 NF- κ B is an important target for therapeutic intervention.

 Unlike other transcription factors, the NF- κ B proteins and other members of the Rel family reside in the cytoplasm in an inactive state but upon activation, they are translocated to the nucleus. The nuclear translocation of Rel proteins is
30 induced by many agents, including inflammatory cytokines (e.g., tumor necrosis factor (TNF), lymphotoxin (LT), and interleukin (IL)-1), mitogens, bacterial products, protein synthesis inhibitors, oxidative stress (H₂O₂), ultraviolet light, and phorbol esters (3, 4). Upon activation of NF- κ B, a large number
35 of genes are induced including various inflammatory cytokines, adhesion molecules, and Rel proteins (for reviews 3 and 4).

-2-

Curcumin (diferuloylmethane) has been shown to block many reactions in which NF- κ B plays a major role. This agent is a major active component of turmeric (*Curcuma longa*) and gives specific flavor and yellow color to curry. The compound has been shown to display anticarcinogenic properties in animals as indicated by its ability to inhibit both tumor initiation induced by benz (a) pyrene and 7,12 dimethylbenz (a) anthracene (5-8) and tumor promotion induced by phorbol esters (9,10), which are known to activate NF- κ B. Curcumin has also been shown to inhibit type 1 human immunodeficiency virus long terminal repeat (HIV-LTR) directed gene expression and virus replication stimulated by TNF and phorbol ester (11), which likewise require NF- κ B activation. The anti-inflammatory and antioxidant properties of curcumin have been well documented (12-14). How these inhibitory responses are modulated by curcumin is not understood.

The prior art is deficient in the lack of effective means of inhibiting the activation of the transcription factor, NF- κ B. The present invention fulfills this longstanding need and desire in the art.

SUMMARY OF THE INVENTION

When activated, NF- κ B, a ubiquitous transcription factor, binds DNA as a heterodimeric complex composed of members of the Rel/NF- κ B family of polypeptides. Because of its intimate involvement in host defense against disease, this transcription factor is an important target for therapeutic intervention. The present invention demonstrates that curcumin (diferuloylmethane), a known anti-inflammatory and anticarcinogenic agent, is a potent inhibitor of NF- κ B activation. Treatment of human myeloid ML-1a cells with TNF rapidly activated NF- κ B, which consists of p50 and p65 subunits, and this activation was inhibited by curcumin. AP-1 binding factors were also found to be down-modulated by curcumin, whereas the Sp1 binding factor was unaffected.

Besides TNF, curcumin also blocked phorbol ester- and hydrogen peroxide-mediated activation of NF- κ B. The TNF-dependent phosphorylation and degradation of I κ B α was not observed in curcumin-treated cells; the translocation of p65

-3-

subunit to the nucleus was inhibited at the same time. The mechanism of action of curcumin was found to be different from that of protein tyrosine phosphatase inhibitors. The present invention indicates that curcumin inhibits NF- κ B activation pathway at a step before I κ B α phosphorylation but after the convergence of various stimuli.

The present invention shows that curcumin is a potent inhibitor of NF- κ B activation induced by various agents. The results also indicate that curcumin inhibits at a step in the signal transduction cascade of NF- κ B activation that occurs before I κ B α phosphorylation but after the point at which various signals transduced by different stimuli converge. The present invention shows that curcumin should be able to modulate NF- κ B-dependent pathological conditions.

In one embodiment of the present invention, there is provided a method of inhibiting the activation of the NF- κ B transcription factor in an animal in need of such treatment comprising the step of administering to said animal a pharmacologically effective dose of curcumin.

In another embodiment of the present invention, there is provided a method of inhibiting the nuclear translocation of the p65 subunit of the NF- κ B transcription factor in a cell or in an animal in need of such treatment comprising the step of administering to said animal a pharmacologically effective dose of curcumin.

In yet another embodiment of the present invention, there is provided a method of inhibiting the phosphorylation and degradation of I κ B α protein in a cell or in an animal in need of such treatment comprising the step of administering to said animal a pharmacologically effective dose of curcumin.

Other and further aspects, features, and advantages of the present invention will be apparent from the following description of the presently preferred embodiments of the invention given for the purpose of disclosure.

BRIEF DESCRIPTION OF THE DRAWINGS

So that the matter in which the above-recited features, advantages and objects of the invention, as well as

-4-

others which will become clear, are attained and can be understood in detail, more particular descriptions of the invention briefly summarized above may be had by reference to certain embodiments thereof which are illustrated in the
5 appended drawings. These drawings form a part of the specification. It is to be noted, however, that the appended drawings illustrate preferred embodiments of the invention and therefore are not to be considered limiting in their scope.

Figure 1 shows the dose response and kinetics of
10 inhibition of TNF-dependent NF- κ B by curcumin. (Figure 1a) ML-1a cells (2×10^6 /ml) were pre-incubated at 37°C for 60 minutes with different concentrations (2 to 60 μ M) of curcumin followed by 30 minutes incubation with 0.1 nM TNF. (Figure 1b) ML-1a cells (2×10^6 /ml) were preincubated at 37°C with 20 μ M curcumin for
15 different times and then measured NF- κ B activation at 37°C for 30 minutes either with or without 0.1 nM TNF. (-) indicates time curcumin was present before the addition of TNF, (0) indicates co-incubation with TNF and (+) indicates time curcumin was added after TNF. For Figure 1c, ML-1a cells (2×10^6 /ml) were
20 incubated at 37°C with 50 μ M curcumin for 60 minutes followed by treatment with 10 nM TNF for different times. After these treatments nuclear extracts were prepared and then assayed for NF- κ B as described below. The arbitrary units represent the relative amounts of the radioactivity present in respective
25 bands.

Figure 2 shows the supershift analysis and specificity of the effect of curcumin on the NF- κ B activation. For Figure 2a, nuclear extracts (NE) were prepared from untreated or TNF (0.1 nM)-treated ML-1a cells (2×10^6 /ml), incubated for 30
30 minutes with antibodies and then assayed for NF- κ B as described below. For Figure 2b, nuclear extracts prepared from TNF pre-treated cells were incubated with different concentrations of curcumin for 15 minutes and then analyzed for NF- κ B by EMSA.

Figure 3 shows the effect of Curcumin on PMA- and H₂O₂-
35 mediated activation of NF- κ B. ML-1a cells (2×10^6 /ml) were preincubated for 60 minutes at 37°C with curcumin (50 μ M) followed by PMA (25 ng/ml) or H₂O₂ (0.5 mM) or indicated

-5-

combinations for 30 minutes and then tested for NF- κ B activation as described below.

Figure 4 shows the effect of curcumin on AP-1 and Sp1 transcription factors. Cells were treated with different concentrations of curcumin for 60 minutes at 37°C, and nuclear extracts were then prepared and used for EMSA of AP-1 and Sp1 transcription factors as described below.

Figure 5 shows the effect of DTT and DMP on the Curcumin and PAO-induced inhibition of NF- κ B activation. ML-1a (2 x 10⁶/ml) were incubated at 37°C for 60 minutes with DTT (100 μ M) or DMP (100 μ M) in the presence of Curcumin (50 μ M) or PAO (2.4 μ M) or indicated combinations followed by 30 minutes incubation with 0.1 nM TNF and then assayed for NF- κ B activation as described below.

Figure 6 shows the effect of curcumin on TNF-induced phosphorylation and degradation of I κ B α and on level of p65 in cytoplasm and nucleus. ML-1a (2 x 10⁶/ml) pretreated (for 60 minutes at 37°C) with or without curcumin (50 μ M) were incubated for different times with TNF (0.1 nM), and then assayed for I κ B α (Figure 6A) and for p65 (Figure 6B) in cytosolic fractions by western blot analysis as described below. ML-1a (2 x 10⁶/ml) pretreated (for 60 minutes at 37°C) with curcumin were incubated with TNF (0.1 nM) for 30 minutes.

Nuclear and cytoplasmic extracts were assayed by western blot analysis for p65. The arbitrary units represent the relative amounts of the respective proteins as described below.

Figure 7 shows the possible site of action of curcumin on TNF- PMA- and H₂O₂- induced NF- κ B activation.

DETAILED DESCRIPTION OF THE INVENTION

In the present invention, the following abbreviations may be used: TNF, tumor necrosis factor; PTPase, protein tyrosine phosphatase; PTK, protein tyrosine kinase; PPase, protein phosphatase; PAO, phenylarsine oxide; DTT, dithiothreitol; DMP, 2, 3-dimercaptopropanol; FBS, fetal bovine serum; HIV-LTR, human immunodeficiency virus-1 long terminal repeat.

-6-

The present invention is directed to a method of inhibiting the activation of the NF- κ B transcription factor in an animal in need of such treatment comprising the step of administering to said animal a pharmacologically effective dose of curcumin. Most preferably, the animal is a human. Preferably, the human has a pathophysiological state selected from the group consisting of toxic/septic shock, graft vs host reaction, radiation damage, atherosclerosis, and cancer. Although the curcumin may be given in any dose which suitably inhibits the activation of the NF- κ B transcription factor, the curcumin is preferably administered in a dose of from about 1 mg/kg to about 100 mg/kg.

The present invention is also directed to a method of inhibiting the nuclear translocation of the p65 subunit of the NF- κ B transcription factor in a cell in an animal in need of such treatment comprising the step of administering to said animal a pharmacologically effective dose of curcumin. For this method, the animal is preferably a human. Preferably, the human has a pathophysiological state selected from the group consisting of toxic/septic shock, graft vs host reaction, radiation damage, atherosclerosis, AIDS, inflammation and cancer. Although the curcumin may be given in any dose which suitably inhibits the activation of the NF- κ B transcription factor, the curcumin is preferably administered in a dose of from about 1 mg/kg to about 100 mg/kg.

The present invention also provides a method of inhibiting the phosphorylation and degradation of I κ B α protein in a cell or in an animal in need of such treatment comprising the step of administering to said animal a pharmacologically effective dose of curcumin. Preferably, the animal is a human. A method of inhibiting the phosphorylation and degradation of I κ B α protein in a cell or in an animal is relevant where the human has a pathophysiological state selected from the group consisting of toxic/septic shock, graft vs host reaction, radiation damage, atherosclerosis, and cancer. Preferably, the curcumin is administered in a dose of from about 1 mg/kg to about 100 mg/kg.

-7-

The following examples are given for the purpose of illustrating various embodiments of the invention and are not meant to limit the present invention in any fashion.

EXAMPLE 1

5 Materials:

Penicillin, streptomycin, RPMI 1640 medium, and fetal calf serum were obtained from GIBCO (Grand Island, NY). Curcumin, glycine, NaCl, and bovine serum albumin were obtained from Sigma Chemical Co. (St. Louis, MO), and
10 phenylarsine oxide from Aldrich Chemicals (Milwaukee, WI). Bacteria-derived recombinant human TNF, purified to homogeneity with a specific activity of 5×10^7 units/mg, was kindly provided by Genentech, Inc. (South San Francisco, CA). Antibody against I κ B α , cyclin D1 and NF- κ B subunits p50 and p65
15 and double stranded oligonucleotides having AP-1 and SP1 consensus sequences were obtained from Santa Cruz Biotechnology (Santa Cruz, CA).

EXAMPLE 2

Cell lines:

20 The cell line employed was ML-1a, a human myelomonoblastic leukemia cell line provided by Dr. Ken Takeda of Showa University, Japan. Cells were routinely grown in RPMI 1640 medium supplemented with glutamine (2 mM), gentamicin (50 mg/ml), and fetal bovine serum (FBS) (10 percent). The cells
25 were seeded at a density of 1×10^5 cells/ml in T25 flasks (Falcon 3013, Becton Dickinson Labware, Lincoln Park, NJ) containing 10 ml of medium and grown at 37°C in an atmosphere of 95 percent air and 5 percent CO₂. Cell cultures were split every 3 or 4 days. Occasionally, cells were tested for mycoplasma contamination
30 using the DNA-based assay kit purchased from Gen-Probe (San Diego, CA).

EXAMPLE 3

Electrophoretic Mobility Shift Assays:

ML-1a cells (2×10^6 cells/ml) were treated
35 separately with different concentrations of an activator at 37°C. Nuclear extracts were then prepared according to Schreiber et al. (15). Briefly, 2×10^6 cells were washed with

-8-

cold phosphate-buffered saline (PBS) and suspended in 0.4 ml of lysis buffer (10 mM HEPES pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 0.5 mM PMSF, 2.0 mg/ml leupeptin, 2.0 mg/ml aprotinin, and 0.5 mg/ml benzamidine). The cells were
5 allowed to swell on ice for 15 minutes, after which 12.5 ml of 10 percent NP-40 was added. The tube was then vigorously mixed on a vortex machine for 10 seconds, and the homogenate was centrifuged for 30 seconds in a microfuge. The nuclear pellet was resuspended in 25 μ l ice-cold nuclear extraction
10 buffer (20 mM HEPES pH 7.9, 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 1 mM PMSF, 2.0 mg/ml leupeptin, 2.0 mg/ml aprotinin, and 0.5 mg/ml benzamidine), and the tube was incubated on ice for 30 minutes with intermittent mixing. The tube was then centrifuged for 5 minutes in a microfuge at 4°C, and the
15 supernatant (nuclear extract) was either used immediately or stored at -70°C for later use. The protein content was measured by the method of Bradford (16).

Electrophoretic mobility shift assays (EMSA) were performed by incubating 4 mg of nuclear extract (NE), with 16
20 fmoles of 32 P end-labeled 45-mer double-stranded NF- κ B oligonucleotide from the HIV-LTR, 5'-TTGTTACAAGGGACTTTCCGCTG
GGGACTTTCCAGGGAGGCGTGG- 3', (17) for 15 minutes at 37°C. The incubation mixture included 2-3 mg of poly (dI-dC) in a binding buffer (25 mM HEPES pH 7.9, 0.5 mM EDTA, 0.5 mM DTT, 1 percent
25 NP-40, 5 percent glycerol, and 50 mM NaCl) (18, 19). The DNA-protein complex formed was separated from free oligonucleotide on 4.5 percent native polyacrylamide gel using buffer containing 50 mM Tris, 200 mM glycine pH 8.5, and 1 mM EDTA (20), and then the gel was dried. A double-stranded mutated
30 oligonucleotide 5'TTGTTACAACTCACTTTCCGCTGCTCACTTTCCAGGGAGGCGTGG-3', was used to examine the specificity of binding of NF- κ B to the DNA. The specificity of binding was also examined by competition with the unlabeled oligonucleotide.

For supershift assays, nuclear extracts prepared from
35 TNF treated cells were incubated with the antibodies against either p50 or p65 subunits of NF- κ B for 30 minutes at room temperature before the complex was analyzed by EMSA (21).

-9-

Antibodies against cyclin D1 and preimmune serum were included as negative controls.

The EMSAs for AP-1 and Sp1 were performed as described for NF- κ B using 32 P end-labeled double-stranded oligonucleotides. Specificity of binding was determined routinely by using an excess of unlabeled oligonucleotide for competition as described earlier (21). Visualization and quantitation of radioactive bands was carried out by a phosphorimager (Molecular Dynamics, Sunnyvale, CA) using 'Image-quant' software.

10

EXAMPLE 4

Electrophoretic Mobility Shift Assays:

ML-1a cells (2×10^6 cells/ml) were treated separately with different concentrations of an activator at 37°C. Nuclear extracts were then prepared according to Schreiber et al. (15). Briefly, 2×10^6 cells were washed with cold phosphate-buffered saline (PBS) and suspended in 0.4 ml of lysis buffer (10 mM HEPES pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 0.5 mM PMSF, 2.0 mg/ml leupeptin, 2.0 mg/ml aprotinin, and 0.5 mg/ml benzamidine). The cells were allowed to swell on ice for 15 minutes, after which 12.5 ml of 10 percent NP-40 was added. The tube was then vigorously mixed on a vortex machine for 10 seconds, and the homogenate was centrifuged for 30 seconds in a microfuge. The nuclear pellet was resuspended in 25 μ l ice-cold nuclear extraction buffer (20 mM HEPES pH 7.9, 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 1 mM PMSF, 2.0 mg/ml leupeptin, 2.0 mg/ml aprotinin, and 0.5 mg/ml benzamidine), and the tube was incubated on ice for 30 minutes with intermittent mixing. The tube was then centrifuged for 5 minutes in a microfuge at 4°C, and the supernatant (nuclear extract) was either used immediately or stored at -70°C for later use. The protein content was measured by the method of Bradford (16).

35

EXAMPLE 5

Western Blotting for I κ B α and p65:

After the NF- κ B activation reaction described above, postnuclear extracts were resolved on 10 percent SDS-polyacrylamide gels for I κ B α . To determine p65 levels,

-10-

nuclear and post nuclear (cytoplasmic) extracts were resolved on 8 percent SDS-polyacrylamide gels. After the gels, the proteins were electrotransferred to nitrocellulose filters, probed with a rabbit polyclonal antibody against I κ B α or against p65, and
5 detected by chemiluminescence (ECL-Amersham) (22). The bands obtained were quantitated using Personal Densitometer Scan v1.30 using Image Quanta software version 3.3 (Molecular Dynamics, Sunnyvale, CA).

EXAMPLE 6

10 Results

The present invention demonstrated the effect of curcumin on the activation of transcription factor NF- κ B. Human ML-1a cells were used for these studies because their response to NF- κ B activation by various stimuli has been well
15 characterized (21-23). The time of incubation and the concentration of the drugs used in the studies had no effect on the cell viability (data not shown).

EXAMPLE 7

Curcumin inhibits TNF-Dependent NF- κ B activation

20 ML-1a cells were preincubated for 1 hour with different concentrations of curcumin followed by treatment with TNF (0.1 nM) for 30 minutes at 37°C. They were then examined for NF- κ B activation by electrophoretic mobility shift assay. The results in Fig. 1a indicate that 40-60 μ M curcumin inhibited most of the
25 TNF response. Curcumin by itself did not activate NF- κ B. The kinetics of inhibition were shown next, incubating the cells with curcumin either for 60, 30 and 10 minutes prior to the addition of TNF, at the same time as the addition of TNF, or 10 minutes after the addition of TNF. The cells were treated with TNF for
30 30 minutes. TNF response was inhibited only when cells were pretreated with curcumin (Figure 1b). Cotreatment of cells with TNF and curcumin was not effective.

A high concentration of TNF (10 nM) can activate NF- κ B within 5 minutes and this induction is higher in its intensity
35 than that obtained with cells using 100-fold lower concentration of TNF for longer time (23). To determine the effect of curcumin on NF- κ B activation at higher TNF concentration and its effect

-11-

on kinetics of TNF-mediated activation of NF- κ B, curcumin-pretreated cells were exposed to 10 nM TNF for various times (Fig. 1c). The induction of NF- κ B by 10 nM TNF was very high and occurred within 5 minutes. Curcumin could completely
5 inhibit the activation of NF- κ B induced by 10 nM as efficiently as it did with 0.1 nM TNF. Thus, curcumin is a very potent inhibitor of NF- κ B activation.

To show that the retarded band observed by EMSA in TNF-treated cells was indeed NF- κ B, the nuclear extracts were
10 incubated with antibody to either p50 (NF- κ B1) or p65 (Rel A) subunits and then carried out EMSA. The results from this experiment (Fig. 2a) show that antibodies to either subunit of NF- κ B shifted the band to higher molecular weight, thus suggesting that the TNF-activated complex consisted of p50 and
15 p65 subunits. Neither preimmune serum nor irrelevant antibody against cyclin D had any effect on the mobility of NF- κ B.

Both TPCK and herbimycin A have been shown to interfere with the binding of NF- κ B to the DNA (25, 52). To determine the effect of curcumin on the binding of NF- κ B to the DNA, the
20 nuclear extracts from TNF-pre-activated cells were incubated with curcumin and then EMSA was performed. The results of this experiment (Fig. 2b) show that curcumin did not modify the ability of NF- κ B to bind to the DNA.

EXAMPLE 8

25 Curcumin Also Blocks Phorbol Ester- and Hydrogen Peroxide-Mediated Activation of NF- κ B:

Besides TNF, NF- κ B activation is also induced by phorbol ester (PMA), and hydrogen peroxide (49). However the initial signal transduction pathway induced by these agents that
30 leads to the NF- κ B activation differs. Therefore, the effect of curcumin on activation of the transcription factor by these various agents was examined. The results shown in Fig. 3 indicate that curcumin completely blocked PMA and hydrogen peroxide-induced activation of NF- κ B. Thus, curcumin is a general
35 suppressor of NF- κ B. activation.

-12-

EXAMPLE 9Curcumin down-modulates AP-1 but not Sp1 transcription factors:

Whether curcumin specifically blocks the activation of NF- κ B or also affects other transcription factors was investigated. Curcumin had no effect on the Sp1 transcription factor (Fig. 4); however, DNA binding of AP-1 transcription factors was found to be down-modulated. This result is in agreement with an earlier report which showed that curcumin not only inhibits the DNA-binding activity of c-Jun/AP-1 binding factors but also down-modulates the level of these factors (24).

EXAMPLE 10Reducing Agents Do Not Reverse the Effect of Curcumin:

It has been shown that agents like TPCK that modify the sulfhydryl group in NF- κ B inhibit its activation but this inhibition is prevented in the presence of DTT and DMP (25, 31). DTT and DMP can also reverse the inhibitory effect of phenylarsine oxide (PAO; a potent PTPase inhibitor) on NF- κ B activation (21). To determine if the inhibitory effect of curcumin on NF- κ B was reversed by these reducing agents, ML-1a cells were treated with curcumin in the presence and absence of either DTT or DMP and then examined for the activation of NF- κ B by TNF. As shown in Fig. 5, DTT and DMP did not reverse the inhibition caused by curcumin but completely reversed the PAO-mediated inhibition. These results thus suggest that the mechanism of action of curcumin is different from that of PTPase inhibitors.

EXAMPLE 11Curcumin inhibits TNF-dependent phosphorylation and degradation of I κ B α and translocation of p65 subunit of NF- κ B to the nucleus:

The translocation of NF- κ B to the nucleus is preceded by the phosphorylation and proteolytic degradation of I κ B α (26). To determine whether the inhibitory action of curcumin was due to its effect on I κ B α degradation, the cytoplasmic levels of I κ B protein were examined by western blot analysis. I κ B α was phosphorylated within 5 minutes of TNF treatment of ML-1a cells and then disappeared within 15 minutes. However, curcumin abolished both the phosphorylation (as indicated by absence of

-13-

the slow migrating band) and degradation of $I\kappa B\alpha$ induced by TNF (Fig. 6A).

The level of p65 in the cytoplasm and in the nucleus was also measured. As expected upon TNF treatment, the level of p65 declined in the cytoplasm with a concurrent increase in the nucleus (Fig 6B and 6C). The treatment of cells with curcumin abolished the TNF-dependent change in the nuclear and cytoplasmic p65 levels. These results show that curcumin inhibits the TNF-induced translocation of p65 to the nucleus and this is consistent with the inhibition of TNF-dependent degradation of $I\kappa B\alpha$ curcumin.

Curcumin is a pharmacologically safe compound with known anti-inflammatory, anticarcinogenic, and free radical scavenger properties (6, 10, 27-30). However, how curcumin carries out these functions is not very clear. NF- κ B plays a pivotal role in cells of the immune system because it is rapidly activated by wide variety of pathogenic signals and functions as a potent and pleiotropic transcriptional activator. Intervention in NF- κ B activation may be beneficial in suppressing toxic/septic shock, graft-vs-host reactions, acute inflammatory reactions, HIV replication, acute phase response and radiation damage.

The present invention demonstrates that curcumin completely blocked the TNF-dependent activation of NF- κ B. The activation induced by various other agents including phorbol ester and H_2O_2 was also inhibited by curcumin. As has been shown with other inhibitors, the effect of curcumin was not due to the chemical modification of NF- κ B proteins (25, 31, 52). The inhibition of NF- κ B activation was accompanied by the inhibition of p65 translocation to the nucleus and of $I\kappa B$ degradation.

Identifying how curcumin blocks the activation of NF- κ B requires an understanding of the mechanism by which various inducers activate this important transcription factor. The role of different TNF-activated signals including acidic and neutral sphingomyelinase-generated ceramides, proteases, serine/threonine protein kinase (PK), protein tyrosine kinase (PTK), protein tyrosine phosphatase (PTPase) and superoxide radicals in the

-14-

activation of NF- κ B have been implicated (1, 21, 22, 32-35). Whether these signals are generated by TNF sequentially or independently of each other, however, is not understood.

5 All three inducers of NF- κ B used in these studies are known to produce reactive oxygen intermediates (ROI). Therefore, it is possible that the effect of curcumin is through quenching of ROI production. The inhibitors of mitochondrial electron transport have been shown to impair the TNF-induced activation of NF- κ B (36), thus also suggesting the role of ROI. Several
10 additional, indirect lines of evidence suggest a role for ROI as a common and critical denominator (40, 41), including evidence that cellular levels of ROI increase in response to TNF, IL-1, PMA, LPS, UV light, and gamma irradiation (for references see 1). But among the various ROI administered to cells in culture, only
15 hydrogen peroxide was found to be an effective activator of NF- κ B (42).

Curcumin may also block NF- κ B activation by inhibiting a protein kinase. In vitro, curcumin has been shown to inhibit both serine/threonine PK and PTK (44). The
20 PK needed for the activation of NF- κ B has not, however, been identified. Although PMA is an activator of PkC, both TNF and H₂O₂ have been shown to activate both PkC and PTK. NF- κ B activation by TNF and H₂O₂ has been shown to be blocked by inhibitors of both PKC and PTK (50). The role of a PTK has
25 also been implicated in NF- κ B activation by ultraviolet light, lipopolysaccharide, hypoxia, and v-src (37-40, 51). TNF-dependent activation of NF- κ B is dependent on erbstatin-sensitive PTK (22). Studies of Schieven et al 1993 (43) showed that PTK inhibitors block
30 gamma-irradiation-induced NF- κ B activation, a stimulant thought to work through the immediate generation of ROI, which suggest that PTK activation may precede ROI generation. Thus there are different early events involved in activation of NF- κ B but all of them may converge to phosphorylate the I κ Ba
35 which precedes its degradation and the subsequent translocation of p65 into the nucleus.

-15-

It has been shown that curcumin not only inhibits the DNA binding of c-jun/AP-1 transcription factor but it also down-modulates c-jun level by preventing its transcription (24). Curcumin did not inhibit the Sp1 transcription factor under the same conditions in which it inhibited NF- κ B and AP-1 transcription factors. Curcumin has also been shown to inhibit TNF and phorbol ester-stimulated type 1 HIV-LTR-directed gene expression and virus replication (11), and this may be mediated through the inhibition of NF- κ B. Recently it has been reported that curcumin can also inhibit nitric oxide synthase (45-47). These observations can be explained based on these results since the expression of this enzyme is NF- κ B dependent. This is consistent with the observation that TPCK, a protease inhibitor that blocks NF- κ B activation, also blocks the expression of nitric oxide synthase (48). TPCK, however, may exert its effect by a different mechanism than curcumin does. It has been shown that TPCK chemically modifies NF- κ B, thus altering its release from I κ Ba (25). Curcumin, however, does not chemically modify the DNA binding properties of NF- κ B.

Another level of modification that could prevent formation of p50/p65 heterodimer is down-modulation of the cytoplasmic pool of p65 subunit of NF- κ B. The present invention, however, shows that p65 was not down-modulated by curcumin but its translocation to the nucleus was inhibited, most likely through inhibition of degradation of I κ B.

The observation that TNF-induced phosphorylation and degradation of I κ B α is abolished by curcumin indicate that the step in the signal transduction pathway of NF- κ B activation inhibited by this agent is at or before the phosphorylation step of NF- κ B (Fig. 8). That it can inhibit NF- κ B activation by diverse agents indicates that this step is after or at the step where the diverse signals converge. Overall, because of its very low pharmacological toxicity and its ability to modulate activation of NF- κ B by various agents, curcumin has a high potential for use in modulating expression of genes regulated by NF- κ B.

-16-

Any patents or publications mentioned in this specification are indicative of the levels of those skilled in the art to which the invention pertains. These patents and publications are herein incorporated by reference to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference.

One skilled in the art will readily appreciate that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. The present examples along with the methods, procedures, treatments, molecules, and specific compounds described herein are presently representative of preferred embodiments, are exemplary, and are not intended as limitations on the scope of the invention. Changes therein and other uses will occur to those skilled in the art which are encompassed within the spirit of the invention as defined by the scope of the claims.

The following references were cited herein:

1. Siebenlist, et al., (1994) Annu. Rev. Cell Biol, 10, 405-455.
2. Baeuerle, et al., (1994) Annu. Rev. Immunol. 12, 141-179.
3. Baeuerle, P. A. (1991) Biochem. Biophys Acta 1072, 63-80.
4. Grilli, M., et al., (1993) Int. Rev. Cytol. 143. 1-62.
5. Huang, et al., (1992) Carcinogenesis 13, 2183-2186.
6. Azuine, M.A. and Bhide, S.V. (1992) Nutr. Cancer 17, 77-83.
7. Azuine, M.A. and Bhide, S.V. (1992) Int. J. Cancer 51, 412-415.
8. Nagbhusan, et al., (1992) J. Am. Coll. Nutr. 11, 192-198.
9. Huang, et al., (1988) Cancer Res. 48, 5941-5946.
10. Conney, et al., (1991) Adv. Enzyme Regul. 31. 385-396.
11. Li, et al., (1993) Proc. Natl. Acad. Sci. U. S. A., 90, 1839-1842.
12. Ammon, et al., (1991) Planta. Med. 57, 1-7.
13. Satoskar, et al., (1986) Int. J. Clin. Pharmacol. Res. 24, 651-654.
14. Shankar, et al., (1980) Indian J. Expt. Biol. 18, 73-75.
15. Schreiber, et al., 1989. Nucleic Acids Res. 17: 6419.

-17-

16. Bradford, M.M. 1976. Anal. Biochem. 72: 248-254.
17. Nabel, G. and D. Baltimore. 1987. Nature 326: 711.
18. Collart, et al., 1990. Mol. Cell Biol. 10: 1498.
19. Hassanain, et al., 1993. Anal. Biochem. 213: 162.
- 5 20. Singh, et al., 1988. Cell 52:415.
21. Singh, et al., (1995) J. Biol. Chem. 270, 10631-10639.
22. Reddy, et al., (1994) J. Biol. Chem., 269, 25369-25372
23. Chaturvedi et al., (1994). J. Biol. Chem. 269:14575-14583.
24. Huang, et al., (1991) Proc. Natl. Acad. Sci. USA, 88,
10 5292-5296.
25. Finco et al., (1994). Proc. Natl. Acad. Sci. USA 91,
11884-11888.
26. Thanos, D. and Maniatis, T (1995) Cell, 80, 529-532.
27. Huang, et al., (1988) Cancer Res. 48, 5941-5946.
- 15 28. Huang, et al., (1992) Carcinogenesis 13, 2183-2186.
29. Takada, et al., (1994) Cancer Res. 54, 4653-4659.
30. Ammon et al., (1993) J. Ethnopharmacol. 38, 113-119
31. Kumar, et al., 1992, Mol. Cell. Biol. 12, 3094-3106.
32. Dressler, et al., (1992) Science, 255, 1715-1718.
- 20 33. Schutze, et al. Cell, 71, 765-76.
34. Mathias, et al., (1991) J. Biol. Chem. 266. 10009-10013.
35. Yang, et al., (1993) J. Biol. Chem. 268, 20520-20523.
36. Schulze-Osthoff, et al., (1993) EMBO J. 12, 3095-3104.
37. Devary, et al., (1993) Science 261, 1442-1445.
- 25 38. Geng, et al., J. Immunol. 151, 6692-6700.
39. Koong, et al., (1994) Cancer Res. 54, 1425-1430.
40. Eicher, et al., (1994) J. Immunol. 152, 2710-2719.
41. Schreck, et al., (1992) J. Exp. Med. 175, 1181-1194.
42. Schreck, et al., (1991) EMBO J. 10, 2247-2258.
- 30 43. Schievien, et al., (1993) Blood 82, 1212-1220.
44. Reddy, S. and Aggarwal, B.B. (1994) FEBS Lett. 341, 19-22.
45. Brouet, et al., (1995) BBRC 206, 533-540
46. Oshima, H. and Bartsch, H. (1994) Mutat. Res. 305, 253-264.
47. Halliwell, B. (1994) The Lancet 344, 721-724.
- 35 48. Kim, et al., (1995) J. Immunol. 154, 4741-4748..
49. Meyer, et al., (1993) EMBO J. 12, 2005-2015.
50. Meichle, et al., (1990) J. Biol. Chem. 265, 8339-8343.

-18-

51. Yanaga, F., and Watson, S. P. (1993) Biochem. J. 298, 733-738.
52. Mahon et al., (1995) Biochemical Soc. Trans. 23, p111S.

-19-

Claims

1. A method of inhibiting the activation of the NF- κ B transcription factor in an animal in need of such treatment comprising the step of administering to said animal a pharmacologically effective dose of curcumin.

2. The method of claim 1, wherein said animal is a human.

3. The method of claim 2, wherein said human has a pathophysiological state selected from the group consisting of toxic/septic shock, graft vs host reaction, radiation damage, atherosclerosis, AIDS, inflammation and cancer.

4. The method of claim 1, wherein said curcumin is administered in a dose of from about 1 mg/kg to about 100 mg/kg.

5. A method of inhibiting the nuclear translocation of the p65 subunit of the NF- κ B transcription factor in a cell in an animal in need of such treatment comprising the step of administering to said animal a pharmacologically effective dose of curcumin.

6. The method of claim 5, wherein said animal is a human.

7. The method of claim 6, wherein said human has a pathophysiological state selected from the group consisting of toxic/septic shock, graft vs host reaction, radiation damage, atherosclerosis, and cancer.

8. The method of claim 5, wherein said curcumin is administered in a dose of from about 1 mg/kg to about 100 mg/kg.

9. A method of inhibiting the phosphorylation and degradation of I κ B α protein in a cell or in an animal in need

-20-

of such treatment comprising the step of administering to said animal a pharmacologically effective dose of curcumin.

10. The method of claim 9, wherein said animal is a human.

5 11. The method of claim 10, wherein said human has a pathophysiological state selected from the group consisting of toxic/septic shock, graft vs host reaction, radiation damage, atherosclerosis, and cancer.

10 12. The method of claim 9, wherein said curcumin is administered in a dose of from about 1 mg/kg to about 100 mg/kg.

2 / 8




FIG. IB




FIG. IC

3 / 8



FIG. 2A





FIG. 2B

**FIG. 3**




FIG. 4

6 / 8




FIG. 5

7 / 8

FIG. 6A




FIG. 6B






FIG. 6C



8 / 8

**FIG. 7**

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US96/14725**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) : A01N 31/08; A61K 31/05; C07K 14/52, 14/47

US CL : 514/731, 886, 824, 917, 886; 530/358, 351

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/731, 886, 824, 917, 886; 530/358, 351

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

MEDLINE, BIOSIS, EMBASE, DERWENT WPI, CHEM AB, APS, search terms: author names, curcumin, diferuloylmethane, NF-kappaB

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	M.M. CHAN. Inhibition of tumor necrosis factor by curcumin, a phytochemical. Biochemical Pharmacology. 26 May 1995, Vol. 49, No. 11, pages 1551-1556, see entire abstract.	1-12
Y	US 5,401,777 A (AMMON ET AL.) 28 March 1995, see entire document.	1-12



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z*	document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means		
P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

30 OCTOBER 1996

Date of mailing of the international search report

08 NOV 1996

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

RON SCHWADRON

Telephone No. (703) 308-0196